Knight Therapeutics (GUD) Stock Price, News & Analysis

Company Overview

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Key Stats

• Today's Range: C$6.27 to C$6.37
• 50-Day Range: C$6.00 to C$6.54
• 52-Week Range: C$5.09 to C$6.55
• Volume: 27,665 shs
• Average Volume: 64,870 shs
• Market Capitalization: C$625.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$7.15
• Consensus Rating: Buy

GUD Stock Analysis - Frequently Asked Questions

How have GUD shares performed this year?

Knight Therapeutics' stock was trading at C$5.34 at the beginning of the year. Since then, GUD shares have increased by 17.6% and is now trading at C$6.28.

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:GUD
• CIK: N/A
• Web: www.gud-knight.com
• Phone: 514-484-4483
• Fax: N/A
• Employees: 725
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Knight Therapeutics: C$7.15
• High Price Target: C$7.50
• Low Price Target: C$6.50
• Potential Upside/Downside: +13.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 62.41
• P/E Growth: -1013.5
• Net Income: -C$30.73 million
• Net Margins: -8.81%
• Pretax Margin: N/A
• Return on Equity: -4.04%
• Return on Assets: 0.51%

Debt

• Debt-to-Equity Ratio: 7.52
• Current Ratio: 3.36
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: C$384.56 million
• Price / Sales: 1.63
• Cash Flow: C$1.64 per share
• Price / Cash Flow: 3.85
• Book Value: C$7.65 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 99,653,000
• Free Float: N/A
• Market Cap: C$627.81 million
• Optionable: Not Optionable
• Beta: 0.22